These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1245 related articles for article (PubMed ID: 15668361)
1. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG; Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361 [TBL] [Abstract][Full Text] [Related]
2. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G; Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472 [TBL] [Abstract][Full Text] [Related]
3. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004 [TBL] [Abstract][Full Text] [Related]
4. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
5. Blood pressure in Native Americans switched from celecoxib to rofecoxib. Fredy J; Diggins DA; Morrill GB Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP; J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774 [TBL] [Abstract][Full Text] [Related]
8. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Goldstein JL; Cryer B; Amer F; Hunt B Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545 [TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445 [TBL] [Abstract][Full Text] [Related]
12. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. Wolfe F; Zhao S; Pettitt D J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928 [TBL] [Abstract][Full Text] [Related]
13. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791 [TBL] [Abstract][Full Text] [Related]
14. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Daniels S; Robbins J; West CR; Nemeth MA Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387 [TBL] [Abstract][Full Text] [Related]
15. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141 [TBL] [Abstract][Full Text] [Related]
16. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912 [TBL] [Abstract][Full Text] [Related]
17. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327 [TBL] [Abstract][Full Text] [Related]
18. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Gibofsky A; Williams GW; McKenna F; Fort JG Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Schnitzer TJ; Kivitz AJ; Lipetz RS; Sanders N; Hee A Arthritis Rheum; 2005 Dec; 53(6):827-37. PubMed ID: 16342089 [TBL] [Abstract][Full Text] [Related]
20. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. Spalding WM; Reeves MJ; Whelton A Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]